Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef, Amsterdam, The Netherlands.
J Interv Cardiol. 2011 Oct;24(5):442-9. doi: 10.1111/j.1540-8183.2011.00665.x.
We assessed the 3-year clinical outcome in our single-center cohort of mainly unselected patients treated with the endothelial progenitor cell capturing stent (ECS). The ECS is coated with CD34+ antibodies specifically targeting the circulating endothelial progenitor cells population to accelerate endothelialization that in turn may prevent the occurrence of in-stent restenosis and stent thrombosis (ST).
All patients in our study had coronary artery lesions that were treated with an ECS. The majority of patients had complex lesions with an estimated high risk of restenosis.
A total of 405 patients were enrolled. The primary end-point of target lesion failure (TLF) was defined as the composite of cardiac death, myocardial infarction, and target lesion revascularization (TLR). At 3 years, TLF was 18.3% and TLR was 14.2%. Early ST occurred in 2 patients. No cases of late and very late definite ST were reported.
This single-center study demonstrates the safety at 3 years of the ECS in an unselected patient population, including a fair number of patients with complex lesions, reflecting daily practice. Our data compare well with drug-eluting stent and bare metal stent registries enrolling unselected patient populations. Importantly, in our analysis, no cases of late or very late definite ST were reported.
我们评估了我们单中心队列中主要未经选择的患者使用内皮祖细胞捕获支架（ECS）治疗的 3 年临床结果。ECS 涂有 CD34+ 抗体，专门针对循环内皮祖细胞群体，以加速内皮化，从而可能预防支架内再狭窄和支架血栓形成（ST）的发生。
我们研究中的所有患者均有冠状动脉病变，采用 ECS 治疗。大多数患者有复杂病变，估计再狭窄风险高。
共纳入 405 例患者。主要终点是靶病变失败（TLF），定义为心脏死亡、心肌梗死和靶病变血运重建（TLR）的复合终点。3 年后，TLF 为 18.3%，TLR 为 14.2%。早期 ST 发生在 2 例患者中。未报告晚期和极晚期明确 ST 的病例。
这项单中心研究表明，在未经选择的患者人群中，ECS 的安全性可维持 3 年，包括相当数量的复杂病变患者，反映了日常实践。我们的数据与接受未经选择的患者人群的药物洗脱支架和裸金属支架注册研究相比结果相当。重要的是，在我们的分析中，未报告晚期或极晚期明确 ST 的病例。
